Delivery Order SPE2DR25D2010-SPE2DR26F4YVE
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,336.48 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes, with a completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a direct fulfillment order under AmerisourceBergen's broader contract vehicle with DLA. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $12,171.08 delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This is a firm fixed price, non-set-aside contract with a completion date of September 8, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly...
- The Defense Logistics Agency Medical Supply Chain awarded a $12,562.42 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. The order, with an ultimate completion date of September 22, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime indefinite delivery vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $11,411.43 under a firm fixed-price contract. The delivery order is non-set-aside and carries an ultimate completion date of September 4, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $11,017.62 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed-price delivery order represents a non-competitive set-aside procurement and is scheduled for completion by June 3, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- The Defense Logistics Agency awarded a delivery order valued at $4,939.02 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The award, issued on August 12, 2025, with an ultimate completion date of August 13, 2025, utilizes firm fixed price pricing with no set-aside designation, indicating competitive award through open competition. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a $16,194.07 delivery order to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes on September 18, 2025, with an ultimate completion date of September 19, 2025. This is a firm fixed price contract with no set-aside designation, competitively awarded to the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The place of performance is listed as Conshohocken, PA. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $9,886.94 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes on October 24, 2025, with an ultimate completion date of October 27, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating a competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the delivery at its corporate...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a $8,210.25 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed-price contract, with an ultimate completion date of September 16, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made on a competitive, non-set-aside basis and represents a child delivery order under the company's larger indefinite delivery...
- SPE2DR25D2010Indefinite Delivery Contract
- SPE2DR25D2010-SPE2DR26F4YVEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $10,744.05 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes on November 4, 2025, with completion expected by November 5, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and fulfillment operations. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vendor agreement running through December 2026 that enables the company to supply pharmaceutical products and medical commodities globally to military healthcare systems. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen maintains an extensive portfolio of competitively awarded contracts with the DLA covering diverse therapeutic products including specialty medications, vaccines, and medical supplies across multiple therapeutic domains. The company's role as a primary pharmaceutical vendor supports healthcare delivery to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.7k | 11/4/25 |